Preclinical Assessment of MEDI0618, A Novel PAR2 Monoclonal Antibody for Treatment of CGRP-dependent and CGRP-independent Migraine-like Pain

被引：0

|

作者：

Kopruszinski, Caroline Machado ^{[1
]}

Linley, John ^{[2
]}

Navratilova, Edita ^{[1
]}

Meno-Tetang, Guy ^{[2
]}

Chessell, Tharani ^{[2
]}

Chessell, Iain ^{[2
]}

Porreca, Frank ^{[1
]}

机构：

[1] Univ Arizona, Tucson, AZ USA

[2] AstraZeneca, BioPharmaceut R&D, Neurosci, Cambridge, England

来源：

CEPHALALGIA | 2023年 / 43卷 / 1supp期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

IHC23-PO-2

引用

收藏

页码：238 / 238

页数：1

相关论文

共 2 条

[1] Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine
Kopruszinski, Caroline M.
Linley, John E.
Thornton, Peter
Walker, Alison S.
Newton, Philip
Podichetty, Sadhana
Ruparel, Radhey Hemendra
de Souza, Luiz Henrique Moreira
Navratilova, Edita
Meno-Tetang, Guy
Gurrell, Ian
Dodick, David W.
Dobson, Claire
Chessell, Tharani
Porreca, Frank
Chessell, Iain
BRAIN, 2025,
[2] A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain
Kopruszinski, Caroline M.
Navratilova, Edita
Swiokla, Juliana
Dodick, David W.
Chessell, Iain P.
Porreca, Frank
CEPHALALGIA, 2021, 41 (03) : 305 - 317